Oraya Therapeutics Completes Enrollment in Pioneering Sham-Controlled Study of Radiation Therapy for Wet AMD
Published: May 18, 2011
NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc. today announced that it has completed enrollment of its INTREPID clinical trial in Europe. The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration (AMD). Oraya’s proprietary IRay™ stereotactic radiotherapy system employs externally delivered robotically controlled low-energy X-rays. The IRay treatment is a one-time non-surgical procedure which may significantly reduce or eliminate the need for subsequent anti-VEGF injections, while maintaining or improving vision outcomes in treated patients. Total procedure time typically takes less than 15 minutes. One year efficacy results of INTREPID will be available in the second quarter of 2012.